Annapolis-based biodefense firm PharmAthene has been awarded an $83.9 million multiyear contract from the National Institutes of Health to develop and advance anthrax vaccine.
The company’s work will focus on a vaccine that can be stored and used without the need for cold temperatures and that requires fewer doses to achieve immunity.
“PharmAthene is strategically building a leading franchise in anthrax countermeasures — a potential billion-dollar market,” company President and Chief Executive Officer David Wright said in a statement.
